Displaying 1 - 1 of 1
| Active Ingredient | NEVIRAPINE |
| Therapeutic Class | NNRTI |
| Indications | For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission. |
| Caution | Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson More ... |
| Dose Range | Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea |
| Drug Interactions | |
| Pregnancy | The human pregnancy data for nevirapine suggest that the risk for embryo–fetal h More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |